Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Now Covered by StockNews.com Analysts

0

Equity research analysts at StockNews.com began to cover the shares of Fresenius Medical Care AG & Co. KGaA (New York Stock Exchange: FMSGet a rating) in a research report delivered Wednesday to clients and investors. The brokerage has placed a “buy” rating on the stock.

Several other research analysts have also recently commented on the FMS. Jefferies Financial Group reduced shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “hold” rating in a Monday, October 10 research report. Credit Suisse Group lowered its price target on shares of Fresenius Medical Care AG & Co. KGaA from €37.00 ($37.00) to €32.00 ($32.00) in a report released Wednesday. Barclays reduced its price target on shares of Fresenius Medical Care AG & Co. KGaA from €40.00 ($40.00) to €36.00 ($36.00) and set an “equal weight” rating for the company in a report on Friday, October 28. UBS Group reduced shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “neutral” rating in a Friday, July 29 report. Finally, Morgan Stanley lowered its price target on shares of Fresenius Medical Care AG & Co. KGaA from €34.00 ($34.00) to €33.00 ($33.00) and set a rating of “equal weight” for the company in a report on Wednesday, November 2. . Two equity research analysts gave the stock a sell rating, eight gave the company a hold rating and three gave the company a buy rating. According to MarketBeat.com, Fresenius Medical Care AG & Co. KGaA currently has an average rating of “Hold” and a consensus price target of $37.87.

Fresenius Medical Care AG & Co. KGaA share performance

NYSE FMS On Wednesday, it fell $0.21 to $14.04. The stock recorded a trading volume of 818,969 shares, compared to an average volume of 832,114 shares. Fresenius Medical Care AG & Co. KGaA has a one-year low of $12.78 and a one-year high of $35.04. The company has a quick ratio of 0.96, a current ratio of 1.34 and a leverage ratio of 0.48. The stock has a market capitalization of $8.23 billion, a price/earnings ratio of 9.96, a P/E/G ratio of 0.79 and a beta of 1.03. The company’s 50-day moving average is $14.72 and its two-hundred-day moving average is $21.27.

Institutional trading of Fresenius Medical Care AG & Co. KGaA

Several institutional investors and hedge funds have recently increased or reduced their stake in the company. US Bancorp DE increased its position in shares of Fresenius Medical Care AG & Co. KGaA by 17.4% in the 2nd quarter. US Bancorp DE now owns 15,767 shares of the company valued at $393,000 after acquiring 2,335 additional shares last quarter. FDx Advisors Inc. acquired a new stake in Fresenius Medical Care AG & Co. KGaA in Q1 for a value of approximately $315,000. Freestone Capital Holdings LLC acquired a new stake in Fresenius Medical Care AG & Co. KGaA in Q1 for approximately $390,000. Guardian Capital Advisors LP increased its position in Fresenius Medical Care AG & Co. KGaA by 10.7% in Q1. Guardian Capital Advisors LP now owns 52,148 shares of the company worth $1,744,000 after buying an additional 5,045 shares last quarter. Finally, Northwestern Mutual Wealth Management Co. strengthened its position in Fresenius Medical Care AG & Co. KGaA by 18.4% in the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 4,706 shares of the company worth $158,000 after buying 730 more shares last quarter. 5.59% of the shares are held by institutional investors and hedge funds.

Fresenius Medical Care AG & Co. KGaA Company Profile

(Get a rating)

Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America and abroad. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; equipment, training and patient support services including clinical monitoring, assisting with follow-up and arranging delivery of supplies to the patient’s home; and contracted dialysis services with hospitals in the United States for hospitalized patients with end-stage renal disease (ESRD) and for patients with acute renal failure.

See also

Analyst Recommendations for Fresenius Medical Care AG & Co. KGaA (NYSE: FMS)

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Before you consider Fresenius Medical Care AG & Co. KGaA, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five actions that top analysts are quietly whispering to their clients to buy now before the market spreads… and Fresenius Medical Care AG & Co. KGaA was not on the list.

While Fresenius Medical Care AG & Co. KGaA currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the five actions here

Share.

Comments are closed.